


**In the claims:**

1. (Original) A compound represented by formula I



or a nontoxic pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof, wherein


$R_a$  and  $R_b$  are independently selected from the group consisting of hydrogen, halogen, hydroxy, nitro, amino, substituted amino, mercapto, polyfluoroalkyl, C<sub>1-6</sub> alkyl, substituted C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, formyl, carboxyl, aryl or heteroaryl;

Linker is selected from the group consisting of C<sub>2</sub> alkyl, C<sub>2</sub> alkenyl, C<sub>2</sub> alkynyl, --C(=O)-NH--, --NH-C(=O)--, --CH<sub>2</sub>O--, --O-C(=O)--, --C(=S)--NH--, --C(=O)-O--, --C(=O)-S--, --S-C(=O)--, --S-CH<sub>2</sub>--, --CH<sub>2</sub>-NH--, --C(=O)-CH<sub>2</sub>--, --NH-C(=S)--, --CH<sub>2</sub>S--; --OCH<sub>2</sub>--, --NHCH<sub>2</sub>;

$X$  is O, S, -C(R<sub>1</sub>)<sub>2</sub>, C=O, -C(R<sub>1</sub>)<sub>2</sub>Y-- or --YC(R<sub>1</sub>)<sub>2</sub>--, wherein Y is selected from the group consisting of O, S and C(R<sub>2</sub>)<sub>2</sub>, wherein R<sub>1</sub> and R<sub>2</sub> are, independently, hydrogen or methyl; and

$Z$  is hydrogen or C<sub>1-6</sub> alkyl.

2. (Original) A compound represented by formula I



or a nontoxic pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof, wherein

$R_a$  and  $R_b$  are independently selected from the group consisting of hydrogen, halogen, hydroxy, nitro, amino, mercapto,  $CF_3$ , C<sub>1-6</sub> alkyl, halosubstituted C<sub>1-6</sub> alkyl, hydroxy-substituted C<sub>1-6</sub> alkyl, aminosubstituted C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, formyl, carboxyl, mono- or di-C<sub>1-6</sub> alkyl-substituted amino, aryl or heteroaryl;

Linker is selected from the group consisting of --CH=CH--, --C≡C--, --C(=O)-NH--, --NH-C(=O)--, --CH<sub>2</sub>O--, --O-C(=O)--, --C(=S)-NH--, --C(=O)-O--, --C(=O)-S--, --S-C(=O)--, --S-CH<sub>2</sub>--, --CH<sub>2</sub>-CH<sub>2</sub>--, --CH<sub>2</sub>-NH--, --C(=O)-CH<sub>2</sub>--, --NH-C(=S)--, --CH<sub>2</sub>S--, --OCH<sub>2</sub>--, --NHCH<sub>2</sub> or --CRc=CRd--, wherein R<sub>c</sub> and R<sub>d</sub> are independently hydrogen or C<sub>1-6</sub> alkyl;

X is O, S, -C(R<sub>1</sub>)<sub>2</sub>, C=O, -C(R<sub>1</sub>)<sub>2</sub>Y-- or --YC(R<sub>1</sub>)<sub>2</sub>--, wherein Y is selected from the group consisting of O, S and C(R<sub>2</sub>)<sub>2</sub>, and R<sub>1</sub> and R<sub>2</sub> are, independently, hydrogen or methyl ; and

Z is hydrogen or C<sub>1-6</sub> alkyl.

3. (Original) The compound of claim 2 wherein X is --C(R<sub>1</sub>)<sub>2</sub>Y-- or --YC(R<sub>1</sub>)<sub>2</sub>--, wherein Y is selected from the group consisting of O, S and C(R<sub>2</sub>)<sub>2</sub> and R<sub>1</sub> and R<sub>2</sub> are, independently, hydrogen or methyl.

4. Cancelled

5. (Original) The compound of claim 3 wherein Linker is --CH=CH- or --C≡C--.

6. Cancelled

7. Cancelled

8. Cancelled

9. Cancelled

10. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier therefor.

11. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 2 and a pharmaceutically acceptable carrier therefor.

12. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 3 and a pharmaceutically acceptable carrier therefor.

13. Cancelled

14. Cancelled

15. Cancelled

16. Cancelled

17. Cancelled

18. Cancelled

19. Cancelled

20. Cancelled